1162 related articles for article (PubMed ID: 36018829)
21. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
[TBL] [Abstract][Full Text] [Related]
22. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
23. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
24. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
[TBL] [Abstract][Full Text] [Related]
25. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
26. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
27. TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity.
Ugamraj HS; Dang K; Ouisse LH; Buelow B; Chini EN; Castello G; Allison J; Clarke SC; Davison LM; Buelow R; Deng R; Iyer S; Schellenberger U; Manika SN; Bijpuria S; Musnier A; Poupon A; Cuturi MC; van Schooten W; Dalvi P
MAbs; 2022; 14(1):2095949. PubMed ID: 35867844
[TBL] [Abstract][Full Text] [Related]
28. Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life.
Saxena A; Wu D
Front Immunol; 2016; 7():580. PubMed ID: 28018347
[TBL] [Abstract][Full Text] [Related]
29. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
Liu H; Saxena A; Sidhu SS; Wu D
Front Immunol; 2017; 8():38. PubMed ID: 28184223
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW
Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of antibody fragment secretion into the Escherichia coli periplasm by co-expression with the peptidyl prolyl isomerase, FkpA, in the cytoplasm.
Levy R; Ahluwalia K; Bohmann DJ; Giang HM; Schwimmer LJ; Issafras H; Reddy NB; Chan C; Horwitz AH; Takeuchi T
J Immunol Methods; 2013 Aug; 394(1-2):10-21. PubMed ID: 23624043
[TBL] [Abstract][Full Text] [Related]
32. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains.
Benedetti F; Stracke F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Biochem Biophys Rep; 2021 Jul; 26():100959. PubMed ID: 33718630
[TBL] [Abstract][Full Text] [Related]
34. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
35. Improving target cell specificity using a novel monovalent bispecific IgG design.
Mazor Y; Oganesyan V; Yang C; Hansen A; Wang J; Liu H; Sachsenmeier K; Carlson M; Gadre DV; Borrok MJ; Yu XQ; Dall'Acqua W; Wu H; Chowdhury PS
MAbs; 2015; 7(2):377-89. PubMed ID: 25621507
[TBL] [Abstract][Full Text] [Related]
36. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
[TBL] [Abstract][Full Text] [Related]
37. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
38. Macrophages are critical effectors of antibody therapies for cancer.
Weiskopf K; Weissman IL
MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
[TBL] [Abstract][Full Text] [Related]
39. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
40. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
